Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

545 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Oestrogen receptor 1 mRNA is a prognostic factor in ovarian cancer patients treated with neo-adjuvant chemotherapy: determination by array and kinetic PCR in fresh tissue biopsies.
Zamagni C, Wirtz RM, De Iaco P, Rosati M, Veltrup E, Rosati F, Capizzi E, Cacciari N, Alboni C, Bernardi A, Massari F, Quercia S, D'Errico Grigioni A, Dietel M, Sehouli J, Denkert C, Martoni AA. Zamagni C, et al. Among authors: rosati f, rosati m. Endocr Relat Cancer. 2009 Dec;16(4):1241-9. doi: 10.1677/ERC-08-0342. Epub 2009 Sep 11. Endocr Relat Cancer. 2009. PMID: 19749010
Early (18)F-2-fluoro-2-deoxy-d-glucose positron emission tomography may identify a subset of patients with estrogen receptor-positive breast cancer who will not respond optimally to preoperative chemotherapy.
Martoni AA, Zamagni C, Quercia S, Rosati M, Cacciari N, Bernardi A, Musto A, Fanti S, Santini D, Taffurelli M. Martoni AA, et al. Among authors: rosati m. Cancer. 2010 Feb 15;116(4):805-13. doi: 10.1002/cncr.24820. Cancer. 2010. PMID: 20052718 Free article.
Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients.
Farolfi A, Petracci E, Gurioli G, Tedaldi G, Casanova C, Arcangeli V, Amadori A, Rosati M, Stefanetti M, Burgio SL, Cursano MC, Lolli C, Zampiga V, Cangini I, Schepisi G, De Giorgi U. Farolfi A, et al. Among authors: rosati m. Front Oncol. 2023 Aug 16;13:1221096. doi: 10.3389/fonc.2023.1221096. eCollection 2023. Front Oncol. 2023. PMID: 37664032 Free PMC article.
Personalized Goal for Dyspnea and Clinical Response in Advanced Cancer Patients.
Mercadante S, Adile C, Aielli F, Lanzetta G, Mistakidou K, Maltoni M, Soares LG, De Santis S, Ferrera P, Rosati M, Rossi R, Casuccio A. Mercadante S, et al. Among authors: rosati m. J Pain Symptom Manage. 2019 Jan;57(1):79-85. doi: 10.1016/j.jpainsymman.2018.10.492. Epub 2018 Oct 16. J Pain Symptom Manage. 2019. PMID: 30336213 Free article.
Prospective comparison of prognostic scores in palliative care cancer populations.
Maltoni M, Scarpi E, Pittureri C, Martini F, Montanari L, Amaducci E, Derni S, Fabbri L, Rosati M, Amadori D, Nanni O. Maltoni M, et al. Among authors: rosati m. Oncologist. 2012;17(3):446-54. doi: 10.1634/theoncologist.2011-0397. Epub 2012 Feb 29. Oncologist. 2012. PMID: 22379068 Free PMC article. Clinical Trial.
545 results